Open AccessClinical Studies of Vaccine Against Smallpox on the Base of Recombinant <i>Vaccinia</i> b7,5S2-S Strain under the Conditions of Double Oral Vaccination
Author(s) -
I. V. Plyasunov,
А. А. Сергеев,
Л. Н. Шишкина,
А. А. Сергеев,
К. А. Титова,
А. П. Агафонов,
N. K. Evtin,
E. A. Stavskiy,
I. G. Drozdov
Publication year - 2010
Publication title -
problemy osobo opasnyh infekcij
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.16
H-Index - 3
eISSN - 2658-719X
pISSN - 0370-1069
DOI - 10.21055/0370-1069-2010-1(103)-51-55
Subject(s) - vaccinia , reactogenicity , vaccination , medicine , virology , immunization , smallpox , poxviridae , orthopoxvirus , virus , smallpox vaccination , antibody , recombinant dna , immunology , biology , biochemistry , gene
Volunteers who had been vaccinated against smallpox in their childhood were orally immunized with Revax-BT vaccine - initially with a small dose, then (in 7, 14, 30, 90 and 180 days) with a large one. Slight reactogenicity was observed after the first vaccination whereas revaccination induced no clinical manifestation. Double immunization with this preparation with 1-2 weeks interval proved to be the most effective method: the protective level of virus-neutralizing antibodies to vaccinia virus (VV) was formed in 90-100 % volunteers in a month after vaccination, and 6 months later this index decreased up to 70 %. The recombinant VV was not registered in the samples of blood, saliva and urine taken from the volunteers after double immunization.